News

CHARLOTTESVILLE, VA / ACCESSWIRE / June 11, 2024 / KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury (ALI). In the U.S., ALI affects 200,000 patients every year and can result from viral infection, sepsis, pneumonia or inhalation of chemical toxins. The most severe form of ALI is referred to as acute respiratory distress syndrome or ARDS.

“There are very limited treatment options for patients with ALI and 40% will die of ARDS,” KeViRx Co-founder John S. Lazo said. “KVX-053 is a host-directed, insult-agnostic small molecule that targets the central pathways that are dysfunctional in ARDS. If we are successful, KVX-053 would be transformative for this disease.”

COLUMBIA, Md., (June 11, 2024) — Program Updates Unveiled for TEDCO’s Maryland Innovation Initiative TEDCO, Maryland’s economic engine for technology companies, announced recent changes to the Maryland Innovation Initiative (MII) program that will enhance efforts to support bringing innovative research to market. A collaboration between the State of Maryland and the five academic research institutions, MII’s goal is to foster the transition of promising technology and research developed in qualifying university labs to the commercial sector.

“With nearly 12 years of progress, research and continued support, we have witnessed several university researcher’s and faculty’s journey to commercial success,” said Renée Winsky, chair of the MII Board of Directors. “With these changes to our processes, we are confident that we will not only continue the overwhelming success but build on it.”

ROCKVILLE, Md., June 12, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as REGENXBIO’s Lead Independent Director, a role previously held by Jerry Karabelas, Ph.D. Dr. Karabelas and Co-Founder Allan Fox, who has served as Chairman since 2020, will remain on the Board.

Biotechnology company innovates treatment for pets with lumps, bumps and cancer

COLUMBIA, Md., (June 11, 2024) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Pre-Seed Builder Fund investment in Kubanda Cryotherapy. The Pre-Seed Builder Fund is housed under TEDCO’s Social Impact Funds, which were created to engage and invest in economically underserved founders and communities.

“Most pet tumors go untreated, and existing treatment options are inaccessible due to high costs and slow healing times,” said Bailey Surtees, CEO of Kubanda Cryotherapy. “We saw this gap in care and built an alternative, non-surgical solution, which offers less down time and better healing outcomes for pets. With TEDCO’s support, we can continue our mission of breaking down barriers to high-quality care.”

BALTIMORE, MD, US, June 10, 2024 /EINPresswire.com/ — Linshom Medical, a start-up medical device company was selected to present at the TechConnect World Innovation Conference on June 18, 2024 in Washington DC. After a competitive evaluation of over 100 applications, Linshom Medical was chosen as 1 of 13 companies to present at the Medical Threat Reduction Challenge, to an expert panel of judges, including federal funders, Medical CBRN Defense Consortium (MCDC) representatives, investors, and private corporations for a chance to earn a portion of $50,000 in non-dilutive prize money.

Linshom Medical is first to deliver an operating room quality respiratory profile to the patient bedside for continuous, predictive respiratory monitoring (CPRM). Recent data shows that the wearable, FDA cleared sensor provides health care providers 15 minutes of advance notice of respiratory decline compared to current standard of care. Clinical care team intervention during this early notice window is typically simple and inexpensive vs. the costly later alternatives when patients experience respiratory decline and are in trouble. These include rapid response activation, rescue events (codes), ICU transfers and potentially death.

— Study Deepens Understanding of Treatments for Alzheimer’s Patients, Enabling More Effective Treatments —

POTOMAC, Md.–(June  10, 2024)–IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

The publication is titled “A study on CYP2C9 polymorphism in Puerto Rican Alzheimer’s Patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol” and is available at https://esmed.org/MRA/mra/article/view/5380.

Company Focused on Bringing Industry-Leading Technology to Market in Food Safety and MedTech Industries 

ALEXANDRIA, Va., June 5, 2024 /PRNewswire/ — HyperSpectral, the world’s first AI-powered spectral intelligence company with hardware-agnostic solutions for particle detection, emerged from stealth today with $8.5 million in a Series A funding round. HyperSpectral’s Series A round was co-led by RRE Ventures and  Kibo Ventures with participation from Correlation Ventures, and GC&H Investments. The funds will allow the company to ramp up development of the technology, hire key talent, and create wider AI datasets through lab partnerships and testing.

PHILADELPHIA, June 07, 2024–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk. In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making.

OXFORD, United Kingdom, June 06, 2024 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS), a biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced the presentation of updated data from two clinical trials in people with chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2024. The presentations include updated interim data from the Phase 2b clinical trial (HBV003), as well as new interim EOT data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in partnership with Arbutus Biopharma (NASDAQ: ABUS), both in people with CHB receiving ongoing SoC NUC therapy.

REPROCELL USA is proud to announce that it has received funding from MSCRF for both proposals it has submitted for the MSCRF’s January 2024 grant cycle. These two grants will help us produce Master Cell Banks (MCB) for cell therapy and enhance our capacity to produce therapeutic cell products.

BELTSVILLE, Md., June 5, 2024 /PRNewswire/ — REPROCELL is a leader in producing clinically relevant human induced pluripotent stem cells (hiPSCs). These hiPSCs are generated from healthy donors that have been screened for eligibility using the questionnaire established by the US Food & Drug Administration (FDA). Further viral testing is performed to satisfy the requirements of FDA, European Medicines Agency (EMA) and Pharmaceutical and Medical Devices Agency (PMDA) of Japan. The first grant titled: “Generation of human iPSC and MSC MCBs and derivative products in an enclosed GMP system” will help REPROCELL offer two GMP grade cell lines in the next 8 to 12 months for commercialization. These products will be tested for quality and ready for off-the-shelf distribution and further differentiation internally, by other companies in Maryland and the rest of the world. This grant is funded by MSCRF under their commercialization grant that provides funding for commercializing the products.